Metabolic and behavioral effects of chronic olanzapine treatment and cafeteria diet in rats.
Olanzapine and highly palatable diets can alter metabolism and brain function. We investigated the interaction of chronic treatment (4 months) with olanzapine and a cafeteria diet on metabolic parameters, memory tasks (spatial and aversive), the elevated plus maze and locomotor activity induced by d-amphetamine. Male Wistar rats were separated into the following groups: standard diet vehicle, standard diet and olanzapine, cafeteria diet vehicle and cafeteria diet and olanzapine. Olanzapine was administered in the drinking water (approximately 1.5 mg/kg/day), and after 3 days of treatment, the rats exhibited an expected anxiolytic effect and reduced amphetamine-induced hyperlocomotion. After 4 months of treatment, cafeteria diet vehicle and cafeteria diet olanzapine rats exhibited an increased body weight and heavier fat pads compared with the standard diet groups. Olanzapine increased only the epididymal and mesenteric fat pads. The cafeteria diet and olanzapine group showed greater glucose intolerance compared with all other groups. The cafeteria diet altered the effects of chronic olanzapine on the performance in the water maze and inhibitory avoidance tasks. Chronic olanzapine treatment failed to affect amphetamine-induced locomotion and to produce anxiolytic effects in the elevated plus maze task, regardless of the diet. Our results suggest that chronic olanzapine caused an increase in fat pads, which is putatively involved in the etiology of many metabolic diseases. Rats on the cafeteria diet were overweight and exhibited glucose intolerance. We did not observe these effects with olanzapine treatment with the standard diet. Moreover, the chronic treatment regimen caused tolerance to the antipsychotic and anxiolytic effects of olanzapine and seemed to potentiate some of the metabolic effects of the cafeteria diet. The cafeteria diet also modified the effects of chronic treatment with olanzapine on cognitive tasks, which may represent an undesirable effect of poor diets in psychiatric patients.
Muller
Alexandre P
AP
Departamento de Bioquímica, ICBS, UFRGS, Programa de Pós Graduação em Ciências Biológicas-Bioquímica, Rua Ramiro Barcelos, Brazil.
Tort
Ana H
AH
Gnoatto
Jussânia
J
Moreira
Julia D
JD
Vinadé
Elsa R
ER
Perry
Marcos L
ML
Souza
Diogo O
DO
Lara
Diogo R
DR
Portela
Luis V
LV
D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001522:Behavior, Animal / Q000187:drug effects; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects; D004032:Diet / Q000523:psychology; D004041:Dietary Fats / Q000009:adverse effects; D004435:Eating / Q000187:drug effects / Q000523:psychology; D057140:Fast Foods / Q000009:adverse effects; D018149:Glucose Intolerance / Q000209:etiology / Q000378:metabolism; D006801:Humans; D008297:Male; D018782:Maze Learning; D009043:Motor Activity / Q000187:drug effects; D009765:Obesity / Q000209:etiology / Q000378:metabolism; D000077152:Olanzapine; D051381:Rats; D017208:Rats, Wistar
D014150:Antipsychotic Agents; D004041:Dietary Fats; D001569:Benzodiazepines; D000661:Amphetamine; D000077152:Olanzapine